. Safe Harbor Statement Ironwood uses non-GAAP financial measures in this presentation, which should be considered only a supplement to, and not a substitute for or superior to, GAAP measures. Refer to the Reconciliation of Non-GAAP Financial Measures to GAAP Results table and to the Reconciliation of Adjusted EBITDA to GAAP net income table and related footnotes on pages 14 and 15 of this presentation. Further, Ironwood considers the net profit for the U.S. LINZESS brand collaboration with AbbVie in assess ...

Trulance (4%) Ibsrela (0%) Volume 1 IQVIA NPA Week Ending November 18, 2022. Strong LINZESS new-to-brand volume and 90-day prescriptions are key indicators of future growth potential 1 IQVIA Patient Insights, Q3 2022. 2 IQVIA Weekly NPA October 2022. 3 IQVIA Quantity Frequency October 2022. LINZESS NBRx Volume Growth1 17 LINZESS 90-Day Prescription ~21%2 120,000 125,000 130,000 135,000 140,000 Q3 2021 Q3 2022 +9% Y/Y 34 35 36 37 38 39 40 41 42 43 44 Average TRx fill size 3 The natural history of Primary Bil ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director of Investor Relations Conference Call Participants Boris Peaker - Cowen Daniel Wolle - JPMorgan Tim Chiang - Capital One Operator Hello. My name is Lisa, and I will be your conference operator today. At this time, I would like to welcome everyone ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Representatives Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Matt Roache - Director of Investor Relations Conference Call Participants David Amsellem - Piper Sandler Operator Good morning. My name is Stephanie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceu ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Hannah Monigatti - JPMorgan David Amsellem - Piper Sandler Tim Chiang - Northland Capital Markets Boris Peaker - Cowen and Company Operator Good morning. My name is Joseph and I will be your conference ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2021 Earnings Conference Call February 17, 2022 8:30 AM ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen & Company Eric Joseph - JPMorgan Timothy Chiang - Northland Capital Unidentified Analyst - Wells Fargo Operator Ladies and gentlemen, good morning. My name is Abby and I will be your conference operator today. At this time ...

| --- | --- | --- | |---------------------------|-------|-------| | | | | | | | | | Ironwood Q4 and Full Year | | | | | | | | | | | | 2021 Investor Update | | | | February 17, 2022 | | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute well against our strategic priorities; the Company's strategy, business, fi ...

Leading in GI through Growth and Innovation J.P. Morgan Healthcare Conference January 12, 2022 PRESENTED BY Tom McCourt, CEO Ironwood Pharmaceuticals, Inc. Safe Harbor Statement 2 This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linac ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2021 Results Conference Call November 4, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Jason Rickard - Chief Operating Officer Conference Call Participants Hannah Adeoye - JPMorgan David Lebowitz - Morgan Stanley Tim Chiang - Northland Capital Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would ...

| --- | --- | |------------------|-------| | | | | | | | | | | | | | | | | Ironwood Q3 2021 | | | | | | Earnings Update | | | November 4, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to max ...